治疗诊断学市场规模、份额及成长分析（依产品、技术、疾病、最终用户及地区划分）－2025-2032年产业预测

预计到 2023 年，全球治疗诊断学市场规模将达到 22 亿美元，到 2024 年将达到 25 亿美元，到 2032 年将达到 68.8 亿美元，在预测期（2025-2032 年）内，复合年增长率为 13.5%。

全球治疗诊断学市场正经历强劲成长，这主要得益于人们对个人化医疗日益增长的需求以及包括癌症和心血管疾病在内的慢性病盛行率不断上升。将诊断和治疗功能整合到单一平台，既能提高治疗效果，又能降低医疗成本。影像学和生物标记的创新进一步拓展了治疗诊断学在已开发市场和新兴市场的应用。然而，高昂的研发成本、复杂的监管流程以及低收入群体认知度不足等挑战依然存在，阻碍了其广泛应用。此外，有限的保险覆盖范围和对专用基础设施的需求也限制了这些解决方案在标准临床环境中的扩充性。透过政策支持、研发投资和策略合作来克服这些障碍，对于市场的持续成长至关重要。

全球治疗诊断学市场驱动因素

对个人化医疗日益增长的需求是治疗诊断学市场的关键驱动力。医疗系统正越来越多地采用整合诊断和治疗调查方法，从而能够根据每位患者独特的基因和分子特征量身定制治疗方案。这种向个人化医疗的转变不仅提高了治疗效果，还最大限度地减少了副作用，最终促进了患者照护的改善。透过关注个人需求，治疗诊断学方法正在改变医疗格局，带来更有效、以病人为中心的治疗。因此，医疗领域对个性化治疗方案的需求正在不断增长。

限制全球治疗诊断学市场发展的因素

全球治疗诊断学市场因其高昂的成本结构而面临许多挑战。对先进成像技术、专用试剂和高技能人员的需求，可能会限制这些先进成像产品的可及性，尤其是在医疗资源匮乏的偏远地区。治疗诊断学解决方案的高昂成本会给医疗系统带来压力，阻碍报销模式的製定，并带来政治风险，从而进一步延缓这些创新技术融入常规临床实践的进程。因此，这些经济障碍可能会显着限制治疗诊断学在患者照护中的广泛应用。

全球治疗诊断学市场趋势

由于人工智慧 (AI) 与治疗系统的融合，全球治疗诊断学市场正经历显着成长。 AI 增强的诊断能力正在推动个人化治疗策略的製定，从而实现更个人化的患者照护。借助包括影像分析和治疗反应预测建模在内的先进数据分析技术，该市场正日益聚焦于精准医疗。 AI 与治疗诊断学的创新结合提供了即时、数据驱动的洞察，从而能够有效管理复杂疾病并优化临床疗效。随着该领域的不断发展，它将继续在全球医疗服务转型和改善患者预后方面发挥引领作用。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术评估
• 监管环境

治疗诊断学市场规模（依产品划分）及复合年增长率（2025-2032 年）

• 市场概览
• 诊断造影显影剂
• 放射性药物和标靶治疗
• 体外诊断/生物标记筛检试剂盒
• 软体和服务

按技术分類的治疗诊断学市场规模及复合年增长率（2025-2032 年）

• 市场概览
• 分子影像（PET/SPECT）
• 放射性配体疗法
• 基于奈米颗粒的治疗诊断学
• 生物标记驱动的伴随诊断

依疾病分類的治疗诊断学市场规模及复合年增长率（2025-2032 年）

• 市场概览
• 肿瘤学
• 神经病学
• 循环系统疾病
• 免疫/发炎性疾病
• 其他的

依最终用户分類的治疗诊断学市场规模及复合年增长率（2025-2032 年）

• 市场概览
• 医院及癌症治疗中心
• 诊断检查室
• 研究和学术机构
• 治疗诊断学中心

治疗诊断学市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2024 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2024 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2022-2024年营收年比比较

主要企业简介

• Bayer AG
• GE Healthcare
• Siemens Healthineers
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Novartis AG
• Telix Pharmaceuticals Limited
• Curium Pharma
• Advanced Accelerator Applications（AAA）
• Bracco Imaging SpA
• Lantheus Holdings
• NanoString Technologies, Inc.
• Roche Holding AG
• Qiagen NV
• Illumina Inc.
• Myriad Genetics, Inc.
• AbbVie Inc.
• Philips Healthcare
• Endocyte, Inc.
• NorthStar Medical Radioisotopes LLC

结论与建议

Global Theranostics Market size was valued at USD 2.2 billion in 2023 and is poised to grow from USD 2.5 billion in 2024 to USD 6.88 billion by 2032, growing at a CAGR of 13.5% during the forecast period (2025-2032).

The global theranostics market is experiencing robust growth, driven by rising demand for personalized medicine and the increasing prevalence of chronic diseases, including cancer and cardiovascular conditions. The integration of diagnostic and therapeutic functions into a single platform enhances treatment efficacy while offering cost-saving benefits in healthcare. Innovations in imaging and biomarkers further broaden the scope of theranostic applications across both developed and emerging markets. However, several challenges persist, including high development costs, intricate regulatory processes, and limited awareness in low-income areas, which hinder widespread adoption. Additionally, restricted reimbursement and the necessity for specialized infrastructure constrain the scalability of these solutions in standard clinical practices. Addressing these barriers through policy support, investment in research and development, and strategic collaborations is crucial for sustainable market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Theranostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Theranostics Market Segments Analysis

Global Theranostics Market is segmented by Product, Technology, Disease, End-User and region. Based on Product, the market is segmented into Diagnostic Imaging Agents, Radiopharmaceuticals & Targeted Therapeutics, IVD/Biomarker Screening Kits and Software & Services. Based on Technology, the market is segmented into Molecular Imaging (PET/SPECT), Radioligand Therapy, Nanoparticle-based Theranostics and Biomarker-driven Companion Diagnostics. Based on Disease, the market is segmented into Oncology, Neurology, Cardiovascular Diseases, Immunological/Inflammatory Disorders and Others. Based on End-User, the market is segmented into Hospitals & Cancer Treatment Centres, Diagnostic Laboratories, Research & Academic Institutes and Theranostics Centres. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Theranostics Market

The surge in demand for personalized medicine stands as a pivotal force propelling the theranostics market forward. Healthcare systems are progressively adopting integrated diagnostic and therapeutic methodologies, enabling treatments to be tailored to the unique genetic and molecular characteristics of each patient. This shift towards personalized medicine not only enhances therapeutic outcomes but also minimizes adverse effects, ultimately fostering improved patient care. By focusing on individual needs, the theranostics approach is reshaping the landscape of healthcare, making it more effective and patient-centric. As a result, the drive for personalized treatment solutions continues to gain momentum in the medical field.

Restraints in the Global Theranostics Market

The global theranostics market faces significant challenges due to its substantial cost structure. The need for sophisticated imaging technologies, unique reagents, and a highly skilled workforce can restrict access to these advanced imaging products, particularly in underserved and rural communities. High expenses linked to theranostic solutions can strain healthcare systems, hindering the progress of reimbursement models and introducing political risks that may further delay the integration and acceptance of these innovations into everyday clinical practice. As a result, these financial barriers can significantly limit the potential for widespread utilization of theranostics in patient care.

Market Trends of the Global Theranostics Market

The Global Theranostics market is experiencing significant growth driven by the integration of artificial intelligence into therapeutic systems. AI-enhanced diagnostic capabilities facilitate tailored treatment strategies, enabling a more personalized approach to patient care. By leveraging advanced data analytics, including the interpretation of imaging and predictive modeling of therapeutic responses, the market is increasingly focused on precision medicine. This innovative intersection of AI and theranostics allows for real-time, data-driven insights that effectively manage complex diseases and optimize clinical outcomes. As this field continues to advance, it positions itself at the forefront of transforming healthcare delivery and improving patient outcomes globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape

Global Theranostics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Diagnostic Imaging Agents
• Radiopharmaceuticals & Targeted Therapeutics
• IVD/Biomarker Screening Kits
• Software & Services

Global Theranostics Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Molecular Imaging (PET/SPECT)
• Radioligand Therapy
• Nanoparticle-based Theranostics
• Biomarker-driven Companion Diagnostics

Global Theranostics Market Size by Disease & CAGR (2025-2032)

• Market Overview
• Oncology
• Neurology
• Cardiovascular Diseases
• Immunological/Inflammatory Disorders
• Others

Global Theranostics Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals & Cancer Treatment Centres
• Diagnostic Laboratories
• Research & Academic Institutes
• Theranostics Centres

Global Theranostics Market Size & CAGR (2025-2032)

• North America (Product, Technology, Disease, End-User)
  • US
  • Canada
• Europe (Product, Technology, Disease, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Technology, Disease, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Technology, Disease, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Technology, Disease, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Telix Pharmaceuticals Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curium Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Accelerator Applications (AAA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco Imaging S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoString Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endocyte, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NorthStar Medical Radioisotopes LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations